Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The trial is conducted in Europe, North America and Asia. The aim of this trial is to
evaluate catridecacog (recombinant factor XIII (rFXIII)) treatment in patients with inherited
FXIII deficiency. It is expected that recombinant FXIII can be used for the prevention of
bleeding episodes.